Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 5/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ADCYAP1R1 | P41586 | 1/20 | 0.30 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6548809 | 0.91 | HTT (0.33) | ALDH1A1MAPTSMN1; SMN2HTTGCGR | |
| SCHEMBL6547769 | 0.87 | ALDH1A1 (0.31) | ALDH1A1MAPTSMN1; SMN2GCGR | |
| SCHEMBL6549004 | 0.87 | NPC1 (0.35) | ALDH1A1MAPTSMN1; SMN2HTTHRH3 | |
| SCHEMBL6548842 | 0.86 | HRH3 (0.43) | MAPTHTTGCGRHRH3MAOA | |
| SCHEMBL6549405 | 0.86 | NPC1 (0.35) | MAPTSMN1; SMN2HTTHRH3MAOA | |
| SCHEMBL6547677 | 0.85 | SMN1; SMN2 (0.33) | ALDH1A1MAPTSMN1; SMN2HTTGCGR | |
| SCHEMBL6549867 | 0.83 | HTT (0.36) | MAPTHTTHRH3MAOAMAOB | |
| SCHEMBL6547615 | 0.83 | GCGR (0.34) | ALDH1A1MAPTSMN1; SMN2HTTGCGR | |
| SCHEMBL6547895 | 0.83 | GCGR (0.34) | ALDH1A1MAPTSMN1; SMN2HTTGCGR | |
| SCHEMBL6547607 | 0.83 | HTT (0.33) | MAPTHTTGCGRHRH3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
| EP-0975586-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | Sumitomo Chemical Company, Limited (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045254-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | ALDH1A1 513/4885MAPT 4623/4885SMN1; SMN2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.